Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | CTSD | P07339 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10778535 | 0.81 | CA2 (0.43) | SMN1; SMN2ALDH1A1HTTLMNACTSD | |
| SCHEMBL7170663 | 0.78 | CTSD (0.36) | ALDH1A1CTSDKDM4E | |
| SCHEMBL13431198 | 0.78 | ALDH1A1 (0.39) | RAB9ASMN1; SMN2ALDH1A1HTTLMNA | |
| SCHEMBL6142485 | 0.74 | — | — | |
| SCHEMBL2378099 | 0.71 | MMP1 (0.40) | RAB9ASMN1; SMN2ALDH1A1NPC1HTT | |
| SCHEMBL10783525 | 0.70 | — | — | |
| SCHEMBL4157715 | 0.70 | LMNA (0.42) | RAB9ASMN1; SMN2ALDH1A1HTTLMNA | |
| SCHEMBL5349924 | 0.69 | — | — | |
| SCHEMBL15821650 | 0.68 | LMNA (0.36) | RAB9ASMN1; SMN2ALDH1A1NPC1HTT | |
| Hydrochloric Acid SCHEMBL5035419 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4578479-A | Process for preparing 1,2,4-triazole-3-carboxamides | UBE INDUSTRIES, LTD. (JP) | 1986-03-25 | — | — | US | claimed |
| CN-1191255-C | Benzodiazepine derivatives as GABA A receptor modulators | HOFFMANN LA ROCHE (CH) | 2005-03-02 | — | — | CN | disclosed |
| EP-1337535-B1 | BENZODIAZEPINE DERIVATIVES AS GABA A RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2004-06-09 | — | — | EP | disclosed |
| US-6743789-B2 | SUBSTITUTED IMIDAZO (1,5-A) (1,2,4) TRIAZOLO (4,3-D) (1,4) BENZODIAZEPINE DERIVATIVES ARE USEFUL FOR TREATING ALZHEIMER'S DISEASE; REACTING A BEZODIAZEPINE DERIVATIVE WITH A HYDRAZIDE DERIVATIVE TO FORM END PRODUCT | HOFFMANN-LA ROCHE INC. | 2004-06-01 | — | — | US | disclosed |
| CN-1474820-A | Benzodiazepine derivatives as GABA A receptor modulators | - | 2004-02-11 | — | — | CN | disclosed |
| EP-1337535-A2 | BENZODIAZEPINE DERIVATIVES AS GABA A RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-27 | — | — | EP | disclosed |
| US-20020103371-A1 | Substituted imidazo [1,5-a] [1,2,4] triazolo [4,3-d] [1,4] benzodiazepine derivatives | HOFFMANN-LA ROCHE INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2002040487-A2 | BENZODIAZEPINE DERIVATIVES AS GABA A RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-05-23 | — | — | WO | disclosed |
| EP-0126326-B1 | PROCESS FOR PREPARING 1,2,4-TRIAZOLE-3-CARBOXAMIDES | UBE INDUSTRIES, LTD. (JP) | 1987-08-05 | — | — | EP | disclosed |
| US-4578479-A | Process for preparing 1,2,4-triazole-3-carboxamides | UBE INDUSTRIES, LTD. (JP) | 1986-03-25 | — | — | US | disclosed |
| EP-0126326-A1 | Process for preparing 1,2,4-triazole-3-carboxamides | UBE INDUSTRIES, LTD. (JP) | 1984-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103371-A1 | Substituted imidazo [1,5-a] [1,2,4] triazolo [4,3-d] [1,4] benzodiazepine derivatives | GABRA5, GABRA1, GABRA4 | RAB9A 1877/4885SMN1; SMN2 2670/4885ALDH1A1 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.